Abstracts tagged "Psoriatic arthritis"

Abstract Number: L13 • 2012 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results of a Phase 3, Randomized, Controlled Trial
Arthur Kavanaugh¹, Philip J. Mease², Juan J. Gomez-Reino³, Adebajo Adewale⁴, Jürgen Wollenhaupt⁵, ChiaChi Hu⁶ and Randall Stevens⁶, ¹UCSD School of Medicine, La Jolla, CA, ²Rheumatology Research, Swedish Medical Center, Seattle, WA, ³Rheumatology, Hospital Clinico Universitario, Santiago, Spain, ⁴University of Sheffield, Sheffield, United Kingdom, ⁵Schön Klinik Hamburg Eilbek, Hamburg, Germany, ⁶Celgene Corporation, Warren, NJ
Background/Purpose: Apremilast, an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate a network of pro- and anti-inflammatory mediators, including those implicated in the etiopathogenesis of…
Abstract Number: 1369 • 2012 ACR/ARHP Annual Meeting
Severe Joint Damage in Psoriatic Arthritis: Mutilans and Ankylosis
Amir Haddad¹, Arane Thavaneswaran¹, Dafna D. Gladman² and Vinod Chandran³, ¹Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Patients with Psoriatic arthritis (PsA) who develop severe joint damage have severe functional disability and increased mortality risk. The most severe form of PsA…
Abstract Number: 1371 • 2012 ACR/ARHP Annual Meeting
Predictors of Erosion-Free Psoriatic Arthritis
Zahi Touma¹, Arane Thavaneswaran², Vinod Chandran³ and D. D. Gladman⁴, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: A number of patients with psoriatic arthritis (PsA) remain erosion-free despite years of disease. We aimed to determine the prevalence, characteristics and predictors of…
Abstract Number: 1348 • 2012 ACR/ARHP Annual Meeting
Diffuse Idiopathic Skeletal Hyperostosis (DISH) in Psoriatic Arthritis
Amir Haddad¹, Arane Thavaneswaran¹, Sergio M.A. Toloza², Vinod Chandran³ and Dafna D. Gladman⁴, ¹Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Medicine, Hospital San Juan Bautista, Catamarca, Argentina, ³Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Spondylitis in Psoriatic Arthritis (PsA) sometimes resembles DISH because of the presence of juxta-vertebral calcification that resemble syndesmophytes. Distinguishing spondylitis from DISH has therapeutic…
Abstract Number: 1044 • 2012 ACR/ARHP Annual Meeting
Ultrasound Scores of Enthesitis and Dactylitis Do Not Correlate with Corresponding Clinical Findings in Psoriasis Arthritis
Rusmir Husic¹, Josef Hermann¹, Judith Gretler², Winfried B. Graninger³ and Christian Dejaco⁴, ¹Rheumatology, Medical University Graz, Graz, Austria, ²Med Univ Klinik Graz, Auenbruggerplatz 15, Graz, Austria, ³Internal medicine/Rheumatology and Immunology, Medical University Graz, Graz, Austria, ⁴Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom
Background/Purpose: To compare sonography verified inflammation of entheses, tendons and joints with corresponding clinical findings in psoriasis arthritis (PsA) patients. Methods: Prospective study of 70 consecutive…
Abstract Number: 1002 • 2012 ACR/ARHP Annual Meeting
Microrna Expression Profiles in Peripheral Blood Mononuclear Cells of Early Onset Psoriatic Arthritis
G. Ciancio¹, Manuela Ferracin², Barbara Zagatti², Elena Saccenti², Valentina Bagnari¹, Ilaria Farina³, Matteo Colina⁴, Marco Seri⁵, Francesco Trotta¹, Massimo Negrini² and Marcello Govoni¹, ¹Department of Clinical and Experimental Medicine, Rheumatology Unit-Azienda Ospedaliera-Universitaria Sant'Anna, Ferrara, Italy, ²Department of Experimental and Diagnostic Medicine, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy, ³A.O.U. S.Anna di Cona, Ferrara, Italy, ⁴Department of Internal Medicine, Section of Internal Medicine A.Ospedale Maggiore, Bologna, Italy, ⁵Department of Gynecology, Obstetrics and Pediatric, St. Orsola-Malpighi, Medical Genetics Unit, Bologna, Italy
Background/Purpose: Micro-RNAs (miRNAs) are small non-coding RNAs that negatively regulate gene expression. It is known that an altered miRNA expression plays an important role in…
Abstract Number: 573 • 2012 ACR/ARHP Annual Meeting
Differential Association Between Human Leukocyte Antigen (HLA) Alleles and Joint Subluxation and Ankylosis in Patients with Psoriatic Arthritis
Vinod Chandran¹, Arane Thavaneswaran², Amir Haddad², Fawnda Pellett³ and Dafna D. Gladman⁴, ¹Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: We have previously reported the association between HLA and KIR gene variants with the development of Arthritis Mutilans (AM) in psoriatic arthritis (PsA). However,…
Abstract Number: 2611 • 2012 ACR/ARHP Annual Meeting
Do Patients with Psoriatic Arthritis Fall Into Distinct Clinical Sub-Groups- a Cluster Analysis?
Arane Thavaneswaran¹, Vinod Chandran² and Dafna D. Gladman³, ¹Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: To determine if demographic and disease characteristics of patients with PsA at presentation to a PsA clinic cluster into distinct groups. Methods: 1058 patients…
Abstract Number: 581 • 2012 ACR/ARHP Annual Meeting
Examining a Role for Th17 Regulation and Toll-Like Receptor Signaling in Psoriatic Arthritis
Fatima Abji¹, Remy Pollock², Fawnda Pellett³, Vinod Chandran⁴ and Dafna D. Gladman², ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a seronegative inflammatory arthritis that develops in 30% of patients with cutaneous psoriasis (PsC). Joint inflammation in PsA is mediated…
Abstract Number: 2557 • 2012 ACR/ARHP Annual Meeting
Ustekinumab in Active Psoriatic Arthritis Including Patients Previously Treated with Anti-TNF Agents: Results of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study
Christopher T. Ritchlin¹, Alice B. Gottlieb², Iain B. McInnes³, Lluis Puig⁴, Proton Rahman⁵, Shu Li⁶, Yuhua Wang⁶, Mittie K. Doyle⁷, Alan Mendelsohn⁸ and Arthur Kavanaugh⁹, ¹Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ²Tufts Medical Center, Boston, MA, ³University of Glasgow, Glasgow, United Kingdom, ⁴Universitat Autònoma de Barcelona, ⁵Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁶Janssen Research and Development, LLC, PA, ⁷Janssen Research and Development, LLC/U of Penn, Spring House/Phila, PA, ⁸Immunology, Janssen Research & Development, LLC, Spring House, PA, ⁹UCSD School of Medicine, La Jolla, CA
Ustekinumab in active psoriatic arthritis including patients previously treated with anti-TNF agents: Results of a Phase 3, multicenter, double-blind, placebo-controlled studyBackground/Purpose: Assess efficacy & safety…
Abstract Number: 590 • 2012 ACR/ARHP Annual Meeting
The Association Between KIR3DL1 Alleles and Psoriatic Arthritis
Remy Pollock¹, Jeffrey Berinstein², Arane Thavaneswaran², Fawnda Pellett³, Dafna D. Gladman⁴ and Vinod Chandran⁵, ¹Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁵Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Killer-cell immunoglobulin-like receptors (KIRs) are activating and inhibitory receptors that regulate NK and NK-T cells, which have been found in psoriatic plaques and synovial…
Abstract Number: 2558 • 2012 ACR/ARHP Annual Meeting
Clinical Response, Drug Survival and Predictors Thereof Among 548 Switchers of Tumor Necrosis Factor Alpha Inhibitor Therapy in Psoriatic Arthritis. Results From the Danish Nationwide Danbio Registry
Bente Glintborg¹, Mikkel Østergaard², Niels Steen Krogh³, Martin Dehn Andersen⁴, Ulrik Tarp⁴, Anne Gitte Loft⁴, Hanne M. Lindegaard⁵, Mette Holland-Fischer⁶, Henrik Nordin⁴, Dorte Vendelbo Jensen⁴ and Merete L. Hetland², ¹Copenhagen University Hospital Gentofte, Copenhagen, Denmark, ²Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ³ZiteLab ApS, Copenhagen, Denmark, ⁴DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, ⁵Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁶Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark
Background/Purpose: Treatment with tumor-necrosis-factor-alpha inhibitors (TNFi) has improved the outcome in patients with psoriatic arthritis (PsA) who have failed treatment with synthetic disease modifying antirheumatic…
Abstract Number: 552 • 2012 ACR/ARHP Annual Meeting
Simple Questions in the Dermatology Office May Reasonably Exclude, but Do Not Reliably Identify Psoriatic Arthritis Patients: Results From the Center of Excellence for Psoriasis and Psoriatic Arthritis
Neha Garg¹, Atul A. Deodhar², Benjamin Ehst³, Andrew Blauvelt⁴, Jennifer Ku⁵ and Brian Truong⁴, ¹Internal Medicine, Division of arthritis and rheumatic diseases, Oregon Health and Sciences University, Portland, OR, ²Oregon Health & Science University, Portland, OR, ³Dermatology, Oregon Health and Sciences University, Portland, OR, ⁴Oregon Health and Sciences University, Portland, OR, ⁵Arthritis and Rheumatic Diseases, Oregon Health and Science University, Portland, OR
Background/Purpose: Psoriatic arthritis (PsA) affects between 10-30% of patients with psoriasis (PsO), but is often missed when assessed in a dermatology clinic. The Center of…
Abstract Number: 2560 • 2012 ACR/ARHP Annual Meeting
Response and Drug Survival of 1^st TNF-Inhibitor in 440 Patients with Psoriatic Arthritis – What Is the Role of Co-Medication with Methotrexate?
Karen M. Fagerli¹, Elisabeth Lie², Désirée van der Heijde³, Marte S. Heiberg⁴, Erik Rødevand⁵, Åse S. Lexberg⁶, Synnøve Kalstad⁷, Knut Mikkelsen⁸ and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Diakonhjemmet hospital, Oslo, Norway, ⁵Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway, ⁶Dept. of Rheumatology, Vestre Viken Hospital, Drammen, Norway, ⁷Dept. of Rheumatology, University Hospital of Northern Norway, Tromsø, Norway, ⁸Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway
Background/Purpose: It is well established that methotrexate (MTX) co-medication improves efficacy of TNF-inhibitors (TNFi) in rheumatoid arthritis, while in ankylosing spondylitis it is widely accepted…
Abstract Number: 569 • 2012 ACR/ARHP Annual Meeting
Ustekinumab Improves Arthritis-Related and Skin-Related Quality of Life in Patients with Active Psoriatic Arthritis: Patient Reported Outcomes From Randomized and Double Blinded Phase III Psummit I Trial
Arthur Kavanaugh¹, Iain B. McInnes², Alice B. Gottlieb³, Lluis Puig⁴, Proton Rahman⁵, Christopher T. Ritchlin⁶, Shu Li⁷, Yuhua Wang⁷, Chenglong Han⁸, Alan Mendelsohn⁹ and Mittie K. Doyle⁷, ¹UCSD School of Medicine, La Jolla, CA, ²Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ³Tufts Medical Center, Boston, MA, ⁴Universitat Autònoma de Barcelona, ⁵Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁶Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁷Janssen Research & Development, LLC, Spring House, PA, ⁸Johnson & Johnson Pharmaceutical Services, LLC., Malvern, PA, ⁹Immunology, Janssen Research & Development, LLC, Spring House, PA
Ustekinumab Improves Arthritis-related and Skin-related Quality of Life in Patients with Active Psoriatic Arthritis: Patient Reported Outcomes from Randomized and Double Blinded Phase III PSUMMIT…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].